Fund Description: Loncar Cancer Immunotherapy ETF is an exchange-traded index fund or Index ETF which is a separate investment portfolio of the ETF Series Solutions, an open-end investment management company. INVESTMENT OBJECTIVE: The Loncar Cancer Immunotherapy ETF seeks to provide investment returns that closely correspond to the price and yield performance of the Loncar Cancer Immunotherapy Index. INDEX DESCRIPTION: The Loncar Cancer Immunotherapy Index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by Loncar Investments, LLC, the Index Provider, as having a high strategic focus on the development of drugs that harness the body’s own immune system to fight cancer (immunotherapy). Loncar identifies companies with a high strategic focus on cancer immunotherapy based on whether they meet one or more of the required criteria. The Index is constructed using an objective, rules-based methodology that begins with an initial universe of all pharmaceutical and biotechnology companies whose equity securities or American Depositary Receipts (ADRs) are listed on a U.S. exchange. The Index may include small-, mid-, and large-capitalization companies. The Index is equal-weighted and is rebalanced and reconstituted on the third Tuesday of June and December. FUND STRATEGY: The Fund attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the Index. Under normal circumstances, at least 80% of the Fund’s total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the Index. The Fund uses a passive management (or indexing) approach to track the performance of the Index. The Fund will generally use a replication strategy to achieve its investment objective, meaning it generally will invest in all of the component securities of the Index. However, the Fund may use a representative sampling strategy, meaning it may invest in a sample of the securities in the Index whose risk, return and other characteristics closely resemble the risk, return and other characteristics of the Index as a whole, when the Fund’s sub-adviser believes it is in the best interests of the Fund (e.g., when replicating the Index involves practical difficulties or substantial costs, an Index constituent becomes temporarily illiquid, unavailable or less liquid, or as a result of legal restrictions or limitations that apply to the Fund but not to the Index). The Fund generally may invest up to 20% of its total assets (exclusive of any collateral held from securities lending) in securities or other investments not included in the Index, but which the Fund’s sub-adviser believes will help the Fund track the Index. FUND MANAGEMENT: Exchange Traded Concepts, LLC serves as the investment advisor, and Vident Investment Advisory, LLC serves as a sub-advisor to the Fund.